SLFN12 and leukemia: Our study reveals stabilization of SLFN12 protein as early as 4 hours after treatment at very low concentrations of BAY 2666605 in leukemia cells both in vitro and in vivo, resulting in potent antileukemic responses and forming the basis for future clinical–translational efforts in that direction.